Vivo Bio Tech Limited

VIVOBIOT6

INE380K01017

Biotechnology & Medical Research

Market Closed - Bombay S.E. Other stock markets 11:00:56 26/06/2024 BST			5-day change	1st Jan Change
40.24 ^INR	-1.49%		+0.15%	+21.57%

05-20	Vivo Bio Tech Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
05-20	Vivo Bio Tech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Vivo Bio Tech Limited Announces the Resignation of Ms. Jyotika Aasat as Company Secretary & Compliance Officer of the Company with Effect from January 02, 2024

December 23, 2023 at 02:23 pm

Vivo Bio Tech Limited announced the resignation of Ms. Jyotika Aasat as Company Secretary & Compliance Officer of the Company with effect from January 02, 2024.

Latest news about Vivo Bio Tech Limited

Vivo Bio Tech Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-20	CI
Vivo Bio Tech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-20	CI
Vivo Bio Tech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12	CI
Vivo Bio Tech Limited Appoints Vaishnavi Kiran Ayinampudi as Company Secretary & Compliance Officer	01-23	CI
Vivo Bio Tech Limited Announces the Resignation of Ms. Jyotika Aasat as Company Secretary & Compliance Officer of the Company with Effect from January 02, 2024	12-23	CI
Vivo Bio Tech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-14	CI
Vivo Bio Tech Limited Announces the Resignation of Hariharan Ravindran as Independent Director	31/08/23	CI
Vivo Bio Tech Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	07/08/23	CI
Vivo Bio Tech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	30/05/23	CI
Vivo Bio Tech Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	30/05/23	CI
Vivo Bio Tech Limited Announces Resignation of Sunder Kanaparthy as Independent Director, Effective from April 1, 2023	31/03/23	CI
Vivo Bio Tech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	13/02/23	CI
Vivo Bio Tech Limited announced a financing transaction	20/12/22	CI
Vivo Bio Tech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/11/22	CI
Vivo Bio Tech Limited Announces Registered Office Address Changes	29/09/22	CI
Vivo Bio Tech Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	10/08/22	CI
Vivo Biotech Acquires Land in Telangana, India for $5 Million	28/02/22	MT
Vivo Bio Tech Acquires Land and Building in Telangana, India for Nearly $5 Million	28/02/22	MT
Vivo Bio Tech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	02/02/22	CI
Vivo Bio Tech to Set Up New Facility in Andhra Pradesh, India	30/01/22	MT
Vivo Bio Tech Limited Executes a Lease Deed with M/S. Andhra Pradesh Med Tech Zone Limited for Setting Up a New Facility at Andhra Pradesh Med Tech Zone-Visakhapatnam	29/01/22	CI
Vivo Bio Tech Limited Announces Change of Registered Office Address	07/01/22	CI
Vivo Bio Tech Limited Announces Board Appointments	07/01/22	CI
Vivo Bio Tech's CFO Tenders Resignation	03/11/21	MT
Vivo Bio Tech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	02/11/21	CI

Vivo Bio Tech Limited is a comprehensive pre-clinical clinical research organization (CRO) providing drug development and discovery services company. It operates in biotechnology segment. The Company offering drug development and discovery services to pharmaceutical and biotech companies. The Company offers services in the areas of in vivo and in vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxic kinetic studies, genotoxicity screening, and analytical services. It provides both regulatory and non-regulatory IND enabling preclinical development services. The Company provides screening and evaluating molecules for various pharmacological and therapeutic properties. Specifically for oncology, it provides design and development of syngeneic / xenograft models for evaluation of anti-cancer agent. The Company also customizes In vivo drug metabolism and pharmacokinetics (DMPK) studies to help profile drug candidate in both rodent and non-rodent animal models.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIVO BIO TECH LIMITED	+21.57%	7.3M
MODERNA, INC.	+30.62%	52.73B
LONZA GROUP AG	+37.49%	39B
IQVIA HOLDINGS INC.	-9.23%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+28.27%	30.38B
CELLTRION, INC.	-12.26%	26.39B
ICON PUBLIC LIMITED COMPANY	+11.61%	26.08B
UNITED THERAPEUTICS CORPORATION	+45.56%	14.15B
MEDPACE HOLDINGS, INC.	+33.03%	12.6B
BIO-TECHNE CORPORATION	-5.35%	11.51B